AVPR2 and autosomal dominant polycystic kidney disease: With the introduction of the vasopressin V2 receptor antagonist tolvaptan into clinical use in autosomal dominant polycystic kidney disease (ADPKD), a disease-specific treatment option was available for the first time for affected individuals who are at risk of rapid progression [1].